1. Takeda Pharmaceutical Co., Japan's largest drugmaker, is spending 19 percent more on drug development this year to find successors to Actos before its best-selling product faces generic competition in 2011.
2. It will provide novel treatment options as early as possible by (a) dropping the development of Actos plus TAK-536 a medicine combining its Actos diabetes pill with an experimental blood pressure drug and (b) prioritizing other projects.
Cutting-edge R&D is good for revenue despite inevitable failures.
[Click here for full story at: BLOOMBERG.COM]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment